[Neoadjuvant Chemotherapy (NC) Response in @entity1 with XXXX According to Immunohistochemical Intrinsic Subtypes (IHC)].

@entity5 @entity1 @entity0 @entity1722
INTRODUCTION: @entity0 is heterogeneous, with different responses to NC even within similar histology and stages. OBJECTIVE: To evaluate clinical/pathological response to NC according to different @entity5 subtypes in Mexican @entity0 @entity1 . @entity1 AND METHODS: Retrospective study of @entity1 with @entity0 stages II-III, and complete immunohistochemistry (IHC), such as hormonal receptors @entity1722 and Ki67, treated with NC and surgery. Descriptive and comparative analyses between different intrinsic subtypes were performed. RESULTS: A total of 117 @entity1 were included with 48.6    10.6 years of age, stage II (24%), and III (76%). We identified 20 (17.1%) cases of luminal A, 37 (31.6%) luminal B @entity1722 -, 13 (11.1%) luminal B @entity1722 +, 12 (10.3%) @entity1722 +, and 35 (29.9%) triple negative. Clinical complete response ( @entity5 and lymph nodes) in luminal A was 10%, in luminal B @entity1722 - 10.8%, luminal B @entity1722 + 15.4%, @entity1722 + 25%, and in triple negative 14.3%. Conservative surgeries were done in 9 (7.7%) @entity1 . There is a weak positive association between Ki67 expression and @entity5 clinical response. Pathological complete response occurred in 8 (6.83%) cases, being more frequent in luminal B @entity1722 + @entity1 (23%). CONCLUSIONS: Pathological complete responses were more often in luminal B @entity1722 + cases.
